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Repetitive behaviors with restricted interests is one of the core criteria for the diagnosis of
autism spectrum disorder (ASD). Current pharmacotherapies that target the dopaminergic
or serotonergic systems have limited effectiveness in treating repetitive behaviors.
Previous research has demonstrated that administration of muscarinic cholinergic receptor
(mAChR) antagonists can exacerbate motor stereotypies while mAChR agonists reduce
stereotypies. The present study determined whether the mAChR agonist, oxotremorine
affected repetitive behaviors in the BTBR T+ tf/J (BTBR) mouse model of autism. To
test the effects of oxotremorine on repetitive behaviors, marble burying and grooming
behavior were measured in BTBR mice and compared to that in C57BL/6J (B6) mice. The
effects of oxotremorine on locomotor activity was also measured. Thirty minutes before
each test, mice received an intraperitoneal (ip) injection of saline, 0.001 mg or 0.01 mg of
oxotremorine methiodide. Saline- treated BTBR mice exhibited increased marble burying
and self-grooming behavior compared to that of saline-treated B6 mice. Oxotremorine
significantly reduced marble burying and self-grooming behavior in BTBR mice, but had
no significant effect in B6 mice. In addition, oxotremorine did not affect locomotor activity
in BTBR mice, but significantly reduced locomotor activity in B6 mice at the 0.01 mg
dose. These findings demonstrate that activation of mAChRs reduces repetitive behavior
in the BTBR mouse and suggest that treatment with a mAChR agonist may be effective in
reducing repetitive behaviors in ASD.
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INTRODUCTION
Autism spectrum disorders (ASDs) represent a cluster of neurode-
velopmental disorders characterized by social and communicative
impairments, as well restricted interests and repetitive behaviors
(RRBs). RRBs are subdivided into lower-order and high-order
behaviors (Lam and Aman, 2007). Lower order RRBs involve
repetitive manipulation of objects, stereotyped movements or
repetitive self-injurious behavior (Lam and Aman, 2007). Higher
order RRBs are characterized by an insistence on sameness, or
rigid adherence to a rule or routine (Turner, 1999; Szatmari et al.,
2006). RRBs are reported to be the most distressing aspect of
ASD for patients and families that profoundly impact daily living
(Bishop et al., 2007).
Current treatments for RRBs have limited effectiveness (Boyd
et al., 2012). Most pharmacotherapies in ASD focus on treating
symptoms by principally modifying dopaminergic and seroton-
ergic signaling (McPheeters et al., 2011). Atypical antipsychotics
have food and drug administration (FDA) indications for treating
irritability but not the core features of ASD (McPheeters et al.,
2011). Selective serotonin reuptake inhibitor (SSRI) medications,
used to reduce restricted interest symptoms, have resulted in
mixed improvements with irritability observed in some individ-
uals (Hollander et al., 2005; Owley et al., 2005, 2010; Henry
et al., 2006; King et al., 2009). An alternative possibility is to treat
RRBs by targeting the cholinergic system. Accumulating evidence
suggests that brain cholinergic abnormalities could explain some
of the pathophysiology in ASD. Post-mortem studies indicate that
there is altered expression of muscarinic and nicotinic cholin-
ergic receptors (Perry et al., 2001; Deutsch et al., 2010). Recent
gene networks that confer risk for ASD include genes related
to cholinergic transmission and these are also highly expressed
in the brain (Voineagu et al., 2011; Ben-David and Shifman,
2012; Lee et al., 2012). Moreover, anti-psychotic treatments which
have significant muscarinic receptor antagonism, e.g., quetiapine,
can exacerbate symptoms in ASD (Martin et al., 1999; Hardan
et al., 2005). Thus, treatments that increase muscarinic choliner-
gic receptor (mAChR) transmission may reduce core symptoms
in ASD.
Animal models are often an important initial step in evaluating
new treatment approaches. The BTBR T+ tf/J (BTBR) mouse
is one preclinical model employed to better understand ASD
because the mouse exhibits a phenotype that is comparable to
the core symptoms in ASD (see Meyza et al., 2013 for review).
Compared to B6 mice, BTBR mice exhibit deficits in social
interactions and communication (McFarlane et al., 2008; Scattoni
et al., 2008, 2011; Pobbe et al., 2010; Silverman et al., 2010;
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Chadman, 2011); restricted interests and behavioral inflexibility
(Moy et al., 2008; Pearson et al., 2011; Amodeo et al., 2012;
Karvat and Kimchi, 2012; Guariglia and Chadman, 2013); as
well as repetitive or stereotyped behaviors, e.g., increased self-
grooming and marble burying (McFarlane et al., 2008; Silverman
et al., 2010; Amodeo et al., 2012; Babineau et al., 2013; McTighe
et al., 2013; Reynolds et al., 2013). Grooming and digging can
be viewed as part of the common behavioral repertoire exhibited
by rodents (Garner and Mason, 2002). Studying these behaviors
in BTBR mice is of particular interest related to ASD because
of the excessive quantity in which these behaviors are expressed
(Yang et al., 2007, 2009; McFarlane et al., 2008; Pobbe et al.,
2010; Pearson et al., 2011; Amodeo et al., 2012), as well as being
exhibited in various contexts and with repeated testing (Yang
et al., 2007, 2009; McFarlane et al., 2008; Pobbe et al., 2010).
For example, Yang et al. (2007) found that BTBR mice showed
higher levels of repetitive grooming than B6 mice when raised
with either a biological BTBR mother, a foster BTBR mother, or
a low grooming B6 mother, demonstrating that excessive self-
grooming in BTBR mice is not attenuated by an environmental
influence such as caregiver.
In addition, recent findings indicate that BTBR mice
exhibit decreased brain acetylcholine levels (McTighe et al.,
2013) and infusion of an acetylcholinestase inhibitor into
the dorsomedial striatum can alleviate a reversal learning
deficit in BTBR mice (Karvat and Kimchi, 2014). How-
ever, unknown is whether cholinergic treatments may also
be effective in reducing repetitive motor behaviors in BTBR
mice. A past study reported that treatment with a mAChR
agonist can reduce stereotyped behaviors in rodents (Wang
and McGinty, 1997). Moreover, post-mortem studies report
reduced mAChR signaling in various brain regions of ASD
patients (Deutsch et al., 2010). Thus, treatment with a mAChR
agonist may be effective in reducing repetitive behaviors in
ASD.
To determine whether treatment with a mAChR agonist
reduces repetitive behaviors, the present experiments examined
whether the mAChR agonist, oxotremorine methoidine alleviates
elevated self-grooming and marble burying in BTBR mice com-
pared to that in B6 mice. To understand whether oxotremorine
treatment has a more general effect on motor behavior, the
effect of oxotremorine on horizontal locomotor activity was also
measured in BTBR and B6 mice.
MATERIALS AND METHODS
ANIMALS
Male C57BL/6J and BTBR mice, 7–8 weeks old, were obtained
from the Jackson Laboratory (Bar Harbor, ME). Mice were singly
housed in plastic cages (28 cm wide × 17 cm long × 12 cm
high) in humidity (30%) and temperature (22◦C) controlled
room with a 12-h light/dark cycle (lights on at 07:00 am).
Ten to fourteen days after arrival behavioral testing procedures
began. Animal care and use was in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals, and was approved by the Institutional Laboratory Ani-
mal Care and Use Committee at the University of Illinois at
Chicago.
DRUGS
Oxotremorine methoidine (Tocris, Ellisville, MO) 0.001
and 0.01 mg/kg was dissolved in 0.9% physiological saline.
Mice received an intraperitoneal (ip) injection at 10 ml/kg
volume.
SPONTANEOUS SELF-GROOMING
The procedure used to measure spontaneous self-grooming
behavior was modified from McFarlane et al. (2008). Mice were
individually placed in a clear plastic cage (28 cm wide × 17 cm
long × 12 cm high) for a total of 20 min. Twenty minutes before
being placed in the plastic cage mice received an ip injection
of either vehicle, 0.001 or 0.01 mg/kg of oxotremorine. The
treatment groups included the following: B6-vehicle (n = 8),
B6-0.001oxotremorine (n = 8), B6-0.01oxotremorine (n = 8),
BTBR-vehicle (n = 9), BTBR-0.001oxotremorine (n = 9), BTBR-
0.01oxotremorine (n = 9). These doses were chosen based on
past studies measuring the effects of oxotremorine on activity in
rodents (Yano et al., 2009; Koda et al., 2011). The plastic cage was
placed in a room separate from the mouse housing room. Subjects
were allowed to freely explore the cage for the entirety of the test.
The first 10 min served as a habituation period. Therefore mice
received injections 30 min prior to measurement of grooming
behavior. During the second 10 min of testing a trained observer
sat approximately 1.6 m from the test cage and recorded cumula-
tive time spent grooming all body regions in real time with a stop-
watch. Grooming behavior included head washing, body groom-
ing, genital/tail grooming and paw and leg licking. Experimenters
were blind to treatment but were not blind to strain because BTBR
mice are dark brown with a cream colored ventral patch while B6
do not have this patch. After each mouse was tested, the cage was
thoroughly cleaned with a 2% ammonium chloride solution.
MARBLE BURYING
Subjects tested for grooming behavior were also tested for marble
burying. The marble burying test occurred 8 days following the
grooming test to ensure there were no potential residual effects
from the initial drug treatment (Birdsall et al., 1978). Subjects
received a different treatment before marble burying from that
administered during the spontaneous self-grooming experiment,
with the exception of three B6 mice. One B6 received vehicle
in both tests and two B6 mice received oxotremorine 0.01 mg
in both tests. For all other mice, approximately half from each
treatment group in the self-grooming test were assigned to one of
the other two treatment groups. For example, for mice receiving
0.001 mg oxotremorine in the self-grooming test, approximately
half were assigned to the vehicle group and half assigned to the
0.01 mg oxotremorine group. With this experimental design, half
of the mice in the oxotremorine treatment groups (low or high
dose) were receiving the drug for the first time. Seven days after
the grooming test, mice were habituated to the plastic container
used for the marble burying test. The same marble burying
test procedure was used as in Amodeo et al. (2012). Mice were
individually placed in a plastic container (46 cm long by 24 cm
wide by 21 cm deep) with 3 cm of clean woodchip bedding
(Northeastern Products, NY). The plastic container was placed
in a room used for behavioral testing. Mice were allowed to
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freely explore a container for 30 min undisturbed. This served
to habituate mice to the chamber. Twenty-four hours later, 20
glass marbles (1.5 cm in diameter) were arranged in five rows
of four. The marbles were placed on top of 3 cm of clean
woodchip bedding. A template was used to ensure that there
was a consistent positioning of marbles. Thirty minutes before
being placed into the test container, mice received an injection
of either vehicle, 0.001, or 0.01 mg of oxotremorine in 0.9%
physiological saline. The treatment groups included the following:
B6-vehicle (n = 8), B6-0.001oxo (n = 8), B6-0.01oxo (n = 8),
BTBR-vehicle (n = 9), BTBR-0.001oxo (n = 9), BTBR-0.01oxo
(n = 9). As in the grooming test, experimenters were blind to
treatment but were not blind to strain. Once a mouse was placed
into the test container a wire lid was placed on top. Mice were
allowed to explore the container and marbles for 30 min. After
30 min, each mouse was removed from the testing container and
returned to their home cage. Marbles were considered buried if
≥2/3 of the surface area was covered in woodchip bedding. The
total number of buried marbles was recorded. Between testing,
marbles were thoroughly cleaned and new bedding was used for
each mouse.
LOCOMOTOR ACTIVITY
A separate group of naïve mice were used to measure locomotor
activity. Testing of locomotor activity was conducted in a black
acrylic rectangular-shaped chamber (76 cm long× 50 cm wide×
30 cm high). Mice were injected with vehicle, 0.001 or 0.01 mg
of oxotremorine 30 min before being placed in the test chamber.
Before mice were introduced to the testing chamber, the entire
apparatus was cleaned with 2% ammonium chloride solution.
Treatment groups included the following: B6-vehicle (n = 8),
B6-0.001oxo (n = 8), B6-0.01oxo (n = 8), BTBR-vehicle (n =
8), BTBR-0.001oxo (n = 8), BTBR-0.01oxo (n = 8). The bottom
of the chamber was divided into nine (25 × 16.5 cm) equally
sized rectangles. After a mouse was placed into the chamber the
experimenter exited the testing room for 20 min. Once the session
ended mice were removed from the test chamber and returned
to the vivarium. Locomotor activity was recorded via camcorder
(Sony Handycam, model DCR-DVD650) stationed above the
chamber. Once the testing session was complete, locomotor activ-
ity was measured by an observer blind to treatment conditions.
The number of lines crossed was calculated. A line cross was
defined as a mouse having all four paws cross a line. The number
of lines crossed was calculated in two separate 10-min blocks.
STATISTICAL ANALYSIS
Separate two-way analysis of variance ANOVAs (strain: B6,
BTBR× treatment: vehicle, 0.001, 0.01 mg/kg oxotremorine) were
conducted for self-grooming and marble burying. A significant
interaction was followed by Tukey HSD post hoc tests to determine
significant treatment differences in both strains. A three-way
ANOVA with repeated measures (strain× treatment × block) was
conducted for locomotor activity. A significant interaction was
followed by Tukey HSD post hoc tests.
RESULTS
SPONTANEOUS SELF-GROOMING
Figure 1 illustrates the findings for spontaneous self-grooming
in BTBR and B6 mice. Vehicle-treated BTBR mice spent
approximately 180 s grooming compared to 20 s in B6 mice.
Oxotremorine decreased self-grooming behavior in BTBR mice
with the largest effect at the 0.01 mg dose which reduced the
time self-grooming to half that observed in vehicle-treated BTBR
mice. In contrast, oxotremorine treatment tended to increase
self-grooming behavior in B6 mice. The main effect of strain was
significant (F(1,45) = 48.26, p< 0.01), but there was no significant
treatment effect (F(2,45) = 1.78, p > 0.05). However there was
a significant strain × treatment interaction (F(2,45) = 6.99, p <
0.01). Post hoc tests indicated that in the vehicle-treated groups,
FIGURE 1 | Oxotremorine treatment attenuates spontaneous
self-grooming behavior in BTBR mice. Mean (±SEM) time spent
grooming all body regions. Self-grooming behavior was measured in
BTBR and B6 mice. Each mouse received an i.p. injection of vehicle,
0.001 or 0.01 mg of oxotremorine 30 min before grooming behavior
was measured. BTBR mice spent significantly more time grooming
compared to that of B6 mice. Vehicle or oxotremorine treatment did not
affect spontaneous grooming behavior in B6 mice. Oxotremorine at
0.01 mg significantly decreased spontaneous grooming in BTBR mice.
B6: vehicle (n = 8), 0.001 (n = 8), 0.01 (n = 8), BTBR: vehicle (n = 9),
0.001 oxo (n = 9), 0.01 oxo (n = 9). ** p < 0.01 vs. B6-vehicle, ## p <
0.01 vs. BTBR-vehicle.
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BTBR mice spent significantly more time self-grooming than
that of B6 mice (p < 0.01). Oxotremorine 0.001 treatment in
BTBR mice reduced self-grooming time, but the difference was
not significantly different from that of vehicle-treated BTBR mice
(p > 0.05). In contrast, oxotremorine 0.01 treatment significantly
reduced self-grooming time compared to that of vehicle treatment
in BTBR mice (p < 0.01). In B6 mice, oxotremorine treatment
tended to increase in self-grooming time, but self-grooming time
for both doses compared to that of vehicle treatment was not sig-
nificant (p’s > 0.05). Thus, oxotremorine treatment reduced self-
grooming behavior in BTBR mice in a dose-dependent fashion.
MARBLE BURYING
The effects of oxotremorine treatment on marble burying
behavior in BTBR and B6 mice are shown in Figure 2. Vehicle-
treated BTBR buried approximately 10 marbles compared to 3
in B6 mice. Oxotremorine dose-dependently decreased marbles
buried in BTBR mice. The oxotremorine 0.001 mg dose reduced
marbles buried to approximately seven. The higher dose of
oxotremorine reduce marble burying to approximately three.
There was a significant main effect for strain (F(1,42) = 35.87,
p < 0.01) and treatment (F(2,42) = 13.12, p < 0.01). Similarly,
there was a significant strain × treatment interaction, (F(2,42) =
3.92, p < 0.05). Post hoc tests indicated that in the vehicle-treated
groups, BTBR mice buried significantly more marbles than that
of B6 mice (p < 0.01). In BTBR mice, oxotremorine 0.001 mg
treatment reduced marble burying, but the difference was not
significantly different from that of vehicle treatment (p > 0.05). In
contrast, oxotremorine 0.01 mg treatment significantly reduced
marble burying compared to that of vehicle treatment in BTBR
mice (p < 0.01). In B6 mice, there was a trend for oxotremorine
treatment to reduce marble burying, although neither dose
compared to that of vehicle treatment was significant (p’s > 0.05).
Thus, oxotremorine treatment reduced marble burying in BTBR
mice in a dose-dependent manner.
One possibility is that the prior treatment received in the
self-grooming test interacted with the treatment received in the
marble burying test to affect performance. As each treatment
group in marble burying included mice that received a mixture
of treatments this could be examined within each treatment
group. In both the low-dose and high-dose oxotremorine group,
BTBR mice that previously received vehicle treatment compared
to mice that previously received the drug exhibited comparable
marble burying performance. Specifically, in the oxotremorine
0.001 mg group, mice that previously received vehicle had a
mean marble burying score of 6.75 ± 2.7 SEM while mice that
previously received the drug had a mean score of 7.75 ± 1.3.
In the oxotremorine 0.01 mg group, previous vehicle treatment
led to a mean score of 3.0 ± 1.5 while previous drug treatment
led to a mean score of 2.5 ± 0.9. In the vehicle-treated group,
mice that previously received the low dose of oxotremorine had
a mean score of 11.0 ± 1.3 while mice that previously received
the high dose of oxotremorine had a mean score of 10.75 ± 0.6.
Thus, previous treatment in the self-grooming test did not affect
performance in the vehicle-treated group or drug groups during
the marble burying test.
A similar pattern was observed for B6 mice. In the
oxotremorine 0.001 mg group, mice that previously received
vehicle had a mean marble burying score of 2.33 ± 0.58 SEM
while mice that previously received the drug had a mean score of
2.25± 1.44. In the oxotremorine 0.01 mg group, previous vehicle
treatment led to a mean score of 1.0 ± 0.41 while previous drug
treatment led to a mean score of 1.33± 1.15. In the vehicle-treated
group, mice that previously received the low dose of oxotremorine
had a mean score of 3.25 ± 0.53 while mice that previously
received the high dose of oxotremorine had a mean score of
3.67± 0.38.
LOCOMOTOR ACTIVITY
Figures 3A,B illustrates the findings for locomotor activity in B6
and BTBR mice, respectively. The locomotor activity was analyzed
FIGURE 2 | Oxotremorine treatment attenuates marble burying in BTBR
mice. Mean (±SEM) marbles buried. Marble burying was measured in BTBR
and B6 mice. Each mouse received an i.p. injection of vehicle, 0.001 or
0.01 mg of oxotremorine 30 min prior to marble exposure. BTBR mice buried
significantly more marbles compared to that of B6 mice. Vehicle or
oxotremorine treatment did not significantly affect marble burying in B6 mice.
Oxotremorine at 0.01 mg significantly decreased marble burying in BTBR
mice. B6: vehicle (n = 9), 0.001 oxo (n = 8), 0.01 oxo (n = 8), BTBR: vehicle
(n = 9), 0.001 oxo (n = 9), 0.01 oxo (n = 9). ** p < 0.01 vs. B6-vehicle, ## p <
0.01 vs. BTBR vehicle.
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FIGURE 3 | Oxotremorine treatment did not affect locomotor activity in
BTBR mice across two consecutive 10-min blocks. Mean (±SEM) lines
crossed. Locomotor activity was measured in B6 and BTBR mice. Each
mouse received an i.p. injection of vehicle, 0.001 or 0.01 mg of oxotremorine
30 min before locomotor activity was measured. (A) Locomotor activity in B6
mice. Activity decreased in the second 10-min block compared to the first.
Oxotremorine 0.01 mg significantly reduced locomotor activity compared to
that of other treatment groups. B6: vehicle (n = 8), 0.001 oxo (n = 8), 0.01 oxo
(n = 8). (B) Locomotor activity in BTBR mice. Activity decreased in the
second 10-min block compared to the first. Oxotremorine treatment did not
affect activity compared to that of vehicle treatment. BTBR: vehicle (n = 8),
0.001 oxo (n = 8), 0.01 oxo (n = 8).
across two 10 min blocks. All groups exhibited similar locomotor
activity, with the exception of oxotremorine 0.01 mg in B6 mice.
There was a significant effect of treatment (F(2,42) = 18.82, p <
0.001), but there was no significant strain effect (F(1,42) = 2.65, p>
0.05). However, the strain× treatment interaction was significant
(F(2,42) = 8.31, p < 0.01). Post hoc analysis revealed that in B6
mice, the oxotremorine 0.01 mg treatment significantly lowered
activity compared to that of all other treatment groups (p’s <
0.05). The analysis further revealed that there was a significant
effect for block (F(1,40) = 110.01, p < 0.001), reflecting that mice
decreased their activity in the second block compared to the first
block. There was also a significant block × strain interaction
(F(1,40) = 5.88, p < 0.05). Post hoc tests revealed that block 2
activity in B6 mice was significantly reduced compared to block
1 activity in B6 and BTBR mice (p’s < 0.05). In addition, block 2
activity was significantly reduced compared to block 1 activity in
BTBR mice (p< 0.05). No other interactions were significant.
DISCUSSION
Individuals with ASD exhibit repetitive, stereotyped behaviors
and cognitive inflexibility that can severely limit daily living
(Bishop et al., 2007; Lam and Aman, 2007; D’Cruz et al., 2013).
Comparable to that observed in ASD, BTBR mice exhibited
increased repetitive behaviors compared to that of B6 mice.
The increased repetitive behaviors in BTBR mice included
both elevated self-grooming and marble burying as observed
in past studies (Yang et al., 2007; Silverman et al., 2010; Gould
et al., 2011; Pearson et al., 2011; Amodeo et al., 2012). Because
past studies in rats indicated that mAChR antagonists increase
stereotyped behavior while mAChR agonists reduce stereotyped
behavior (Wang and McGinty, 1997; Laviolette et al., 2000; Aliane
et al., 2011), these studies investigated whether treatment with the
non-specific, mAChR agonist, oxotremorine reduced repetitive
behaviors in BTBR mice. Acute oxotremorine treatment,
dose-dependently, attenuated the elevated self-grooming and
marble-burying behavior in BTBR mice. These findings suggest
that activation of mAChR can attenuate certain repetitive
behaviors.
A past study examined the self-grooming microstructure in
BTBR mice (Pearson et al., 2011). This analysis showed that BTBR
mice exhibit an increase in almost all grooming subtypes with
the exception of paw licking. Examination of the self-grooming
microstructure also revealed that BTBR mice display a decrease in
the percentage of incorrect transitions across the different groom-
ing subtypes. Mice commonly groom in a cephalocaudal fash-
ion starting with head washing and concluding with tail/genital
licking. The present study did not examine the self-grooming
microstructure or the grooming sequence. Thus, unknown is
whether oxotremorine preferentially affected grooming subtypes
or broadly decreased grooming subtypes. Further, unclear from
the present study is whether oxotremorine altered the grooming
sequence in BTBR mice in any way. Future studies investigating
the effects of mAChR treatment on repetitive behaviors can
address how mAChR agonists may alter self-grooming subtypes
and self-grooming sequence. However, the present results indicate
that oxotremorine treatment decreases self-grooming duration in
BTBR mice without the highest dose of oxotremorine having an
effect on locomotor activity. Taken together, the results suggest
that mAChR agonist treatment may be effective in reducing lower-
order repetitive behaviors in ASD.
In contrast to BTBR mice, B6 mice exhibited minimal groom-
ing behavior as reported previously (Yang et al., 2007; McFarlane
et al., 2008; Silverman et al., 2010; Pearson et al., 2011; Amodeo
et al., 2012). Oxotremorine treatment actually showed a trend
toward increasing grooming behavior in B6 mice. This increase in
grooming behavior may explain why an oxotremorine injection in
B6 mice tended to decrease marble burying and locomotor activ-
ity. The opposite effects of oxotremorine on grooming behavior in
BTBR and B6 mice may suggest that there is an inverted U-shaped
curve for mAChR activation to minimize grooming behavior. In
particular, B6 mice may typically exhibit the “optimal level” of
mAChR activity, but when treated with a mAChR agonist, i.e.,
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oxotremorine, this increases mAChR activation above the optimal
levels leading to increased grooming. Conversely, BTBR mice
may have lower levels of mAChR activation leading to increased
grooming, but treatment with oxotremorine brings mAChR activ-
ity into the optimal range that then decreases grooming behavior.
Therefore, either too little or too great mAChR activation may
lead to increased grooming behavior.
Comparable to that observed with self-grooming,
oxotremorine 0.01 mg significantly reduced marble burying
in BTBR mice. In B6 mice, there was a trend for oxotremorine
0.01 mg to reduce marble burying. Relative to BTBR mice, B6
mice display low levels of marble burying. The lower level of
marble burying in B6 mice is consistent with previous studies
(Amodeo et al., 2012; Schwartzer et al., 2013). However, because
B6 mice exhibit a low level of marble burying this may obscure a
drug effect in reducing marble burying. Another potential issue
in interpreting the marble burying results is that mice were tested
on marble burying following a self-grooming test. One possibility
is that a previous treatment in the self-grooming test affected
marble burying behavior. However, examination of the previous
treatment received indicated that this did not influence marble
burying behavior. This was the case for both BTBR mice and B6
mice. Also worth noting is that the number of marbles buried
by vehicle-treated BTBR mice was comparable to that buried by
drug-naïve BTBR mice in previous studies (Gould et al., 2011,
2012; Amodeo et al., 2012; Schwartzer et al., 2013). Thus, despite
vehicle-treated BTBR mice in the marble burying test receiving
either the low or high dose of oxotremorine in the self-grooming
test, this did not alter their marble burying behavior compared
to past observations in BTBR mice. Again, because oxotremorine
treatment had no effect on locomotor activity in BTBR mice, the
drug-induced reduction in marble burying behavior can not be
explained by a more general reduction in activity. Instead, the
results suggest that activation of mAChRs selectively modulated
repetitive behaviors in BTBR mice.
The current findings complements a recent study that
demonstrated treatment with the acetylcholinesterase inhibitor,
donepezil, can improve behavioral rigidity as measured by rever-
sal learning in BTBR mice (Karvat and Kimchi, 2014). Because
acetylcholinesterase inhibitors leads to a non-specific increase
in acetylcholine levels unknown is whether specific cholinergic
receptors mediate these behavioral effects. The current exper-
iments investigating the effects of oxotremorine demonstrate
that activation of mAChRs is sufficient to attenuate repetitive
behaviors in BTBR mice. Although stimulation of mAChRs was
able to attenuate repetitive behaviors, this does not rule out that
nicotinic cholinergic receptors may also play a role in affecting
repetitive behaviors. Nicotine treatment in rats has shown to
reduce certain stereotyped or repetitive behaviors (Zarrindast
et al., 1999; Tizabi et al., 2002). Moreover, oxotremorine is a
non-specific mAChR agonist, therefore still to be determined is
whether specific mAChR subtypes may be sufficient to alleviate
repetitive behaviors.
Previous studies investigated the effects of a M1 mAChR
agonist on drug-induced or spontaneous grooming behavior in
rodents (Bhattacharya and Sen, 1991; Inan et al., 2011). In both
studies, McN-A-343 significantly reduced grooming behavior.
Unclear is whether other muscarinic receptor subtypes may also
be sufficient to reduce repetitive behaviors. There is evidence
that targeting M5 mAChR can affect locomotion (Wang et al.,
2004; Steidl and Yeomans, 2009), but unknown is whether this
is restricted to general ambulation or also to motor stereotyped
behavior. Repetitive behaviors in ASD have been separated into
lower-order and higher-order repetitive behaviors (Bodfish et al.,
2000; Lam and Aman, 2007). Lower order repetitive behaviors
can include stereotyped movements or repetitive self-injurious
behavior. Higher order RRBs instead are characterized by an
“insistence on sameness” or rigid adherence to a rule or routine
(Lam and Aman, 2007; Boyd et al., 2012). The findings with
McN-343 suggest that treatment with a M1 mAChR agonist may
be effective in treating lower-order repetitive behaviors in ASD.
However, a recent study reported that the partial M1 mAChR
agonist, CDD-102A, enhances set-shifting in rats (Ragozzino
et al., 2012). Thus, treatment with a M1 mAChR agonist may be
effective in treating both lower-order and higher-order repetitive
behaviors.
The present studies indicated that a systemic injection of
oxotremorine reduced repetitive behaviors in BTBR mice. The
dorsomedial striatum may be a key anatomical site in which
oxotremorine acts to affect repetitive behaviors. This is because
drug treatments that increase stereotyped behaviors decrease
acetylcholine output from this region (Aliane et al., 2011). Fur-
thermore, destruction of cholinergic interneurons or injection
of a mAChR antagonist in the dorsomedial striatum leads to
increased repetitive behaviors that is alleviated by drug treatments
that increase dorsomedial striatal acetylcholine output (Aliane
et al., 2011). Cholinergic signaling in the dorsomedial striatum
may not only be important for minimizing repetitive motor
behaviors, but also for enabling cognitive flexibility. Karvat and
Kimchi (2014) showed that donepezil injections into the dorso-
medial striatum also improved reversal learning in BTBR mice.
This effect of donepezil is consistent with past results showing that
enhancing acetylcholine efflux in the rat dorsomedial striatum
improves reversal learning while blocking acetylcholine efflux in
this region impairs reversal learning (Palencia and Ragozzino,
2006; Ragozzino et al., 2009). Moreover, recent findings sug-
gest that activation of M1 mAChRs in the dorsomedial stria-
tum may mediate acetylcholine effects on cognitive flexibility
(Tzavos et al., 2004; McCool et al., 2008; Ragozzino et al., 2012).
Thus, treatment with a mAChR agonist may be effective in
alleviating stereotyped motor behaviors and cognitive flexibility
deficits.
To date, there exists some evidence, but not extensive find-
ings, suggesting altered brain cholinergic transmission in ASD.
In particular, there are results from gene networks that confer
risk of ASD that include genes related to cholinergic transmis-
sion (Voineagu et al., 2011; Ben-David and Shifman, 2012; Lee
et al., 2012) and post-mortem studies indicating reduced brain
mAChR expression in ASD individuals (Deutsch et al., 2010).
However, there is not a definitive understanding of whether
pathophysiology of the brain cholinergic system exists in ASD.
Related, unknown is whether there are specific brain choliner-
gic systems that are altered in the disorder and/or if a brain
acetylcholine pathophysiology exists and how it may relate to
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particular symptoms in ASD. Addressing these issues can further
our understanding of the etiology of ASD and help develop
new effective therapeutics. The employment of animal models
can help address these issues. The present findings in the BTBR
mouse, a model of idiopathic autism, reveal that the non-specific
mAChR agonist, oxotremorine attenuates repetitive motor behav-
iors without affecting general ambulation. Thus, treatment with a
mAChR agonist may be effective in reducing repetitive behaviors
in ASD.
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